Developments Telix in PSMA collaboration with Profound Medical and other prostate cancer therapy players Telix Pharmaceuticals (ASX:TLX, NASDAQ:TLX) announced that it has entered into letters of intent to pursue collaborations to explore the investigational use of its PSMA-PET imaging agents Gozellix (kit for the... May 15, 2026